Article
Construction of a novel cell-based assay for the evaluation of anti-EGFR drug efficacy against EGFR mutation.
Oncology reports - 1 Jan 2017
Hoshi Hirotaka, Hiyama Gen, Ishikawa Kosuke, Inageda Kiyoshi, Fujimoto Jiro, Wakamatsu Ai, Togashi Takushi, Kawamura Yoshifumi, Takahashi Nobuhiko, Higa Arisa, Goshima Naoki, Semba Kentaro, Watanabe Shinya, Takagi Motoki
Abstract excerpt
Epidermal growth factor receptor (EGFR) overexpression and EGFR-mediated signaling pathway dysregulation have been observed in tumors from patients with various cancers, especially non-small cell lung cancer. Thus, several anti-EGFR drugs have been developed for cancer therapy. For patients with known EGFR activating mutations (EGFR exon 19 in-frame deletions and exon 21 L858R substitution), treatment with an...
Topics
- Afatinib
- Antineoplastic Agents
- Cell Culture Techniques
- Cells, Cultured
- Drug Evaluation, Preclinical
- Drug Resistance, Neoplasm
- ErbB Receptors
- Erlotinib Hydrochloride
- Gefitinib